Oral Carnitine in Heart Failure Patients

Recruiting now · Early Phase 1

Conditions studied: Heart Failure, Carnitine Deficiency

In brief

Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.

Key facts

Study ID

NCT07201714

Run by

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

People needed

20

Starts

2025-11-12

Expected to finish

2026-12-31

Last updated by the study team

2026-04-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome
• Stage 1, 2, 3a, 3b, or 4 chronic kidney disease
• Age ≥ 18 years
• Able to speak and read English
• Willing and able to provide consent

You may not qualify if…

• Estimated GFR <15 mL/min/1.73m2 or Stage 5 chronic kidney disease
• Currently undergoing renal replacement therapy of any kind
• Pregnant, breastfeeding or intending pregnancy
• History of seizures of any type
• Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone
• Unable to provide consent

Where it is running

• London Health Sciences Centre — London, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.